Novartis adds another Cosentyx approval with FDA nod
This article was originally published in Scrip
Executive Summary
The FDA on 21 January gave its blessing to Novartis to market Cosentyx (secukinumab) as a treatment for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.